CN118076583A - 用于治疗癌症的方法和组合物 - Google Patents

用于治疗癌症的方法和组合物 Download PDF

Info

Publication number
CN118076583A
CN118076583A CN202280068270.9A CN202280068270A CN118076583A CN 118076583 A CN118076583 A CN 118076583A CN 202280068270 A CN202280068270 A CN 202280068270A CN 118076583 A CN118076583 A CN 118076583A
Authority
CN
China
Prior art keywords
days
group
administration
independently
weeks
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280068270.9A
Other languages
English (en)
Chinese (zh)
Inventor
史蒂文·弗鲁赫特曼
马修·帕里斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Anconova Treatment Co
Original Assignee
Anconova Treatment Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anconova Treatment Co filed Critical Anconova Treatment Co
Publication of CN118076583A publication Critical patent/CN118076583A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C317/28—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to acyclic carbon atoms of the carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202280068270.9A 2021-08-12 2022-08-11 用于治疗癌症的方法和组合物 Pending CN118076583A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163232409P 2021-08-12 2021-08-12
US63/232,409 2021-08-12
PCT/US2022/040092 WO2023018891A1 (en) 2021-08-12 2022-08-11 Methods and compositions for treating cancer

Publications (1)

Publication Number Publication Date
CN118076583A true CN118076583A (zh) 2024-05-24

Family

ID=85200519

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280068270.9A Pending CN118076583A (zh) 2021-08-12 2022-08-11 用于治疗癌症的方法和组合物

Country Status (11)

Country Link
US (1) US20240299326A1 (https=)
EP (1) EP4384498A1 (https=)
JP (1) JP2024531238A (https=)
CN (1) CN118076583A (https=)
AU (1) AU2022326485A1 (https=)
CA (1) CA3228644A1 (https=)
CO (1) CO2024002786A2 (https=)
GB (1) GB2628229A (https=)
IL (1) IL310759A (https=)
MX (1) MX2024001935A (https=)
WO (1) WO2023018891A1 (https=)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5156389B2 (ja) * 2005-01-05 2013-03-06 テンプル・ユニバーシティ−オブ・ザ・コモンウェルス・システム・オブ・ハイアー・エデュケイション 薬剤耐性増殖性疾患の治療剤
WO2014089483A1 (en) * 2012-12-07 2014-06-12 Onconova Therapeutics, Inc. Methods and compositions for treatment of cancer
JP2018530590A (ja) * 2015-10-14 2018-10-18 タリックス ファーマシューティカルズ リミテッド 表皮水疱症の処置のための方法及び組成物
CA3076610A1 (en) * 2017-09-22 2019-03-28 University Of Miami Methods and compositions for the treatment of epidermolysis bullosa

Also Published As

Publication number Publication date
WO2023018891A1 (en) 2023-02-16
US20240299326A1 (en) 2024-09-12
GB2628229A (en) 2024-09-18
AU2022326485A1 (en) 2024-02-29
MX2024001935A (es) 2024-03-21
CO2024002786A2 (es) 2024-03-18
GB202402730D0 (en) 2024-04-10
CA3228644A1 (en) 2023-02-16
WO2023018891A8 (en) 2023-09-21
IL310759A (en) 2024-04-01
JP2024531238A (ja) 2024-08-29
EP4384498A1 (en) 2024-06-19

Similar Documents

Publication Publication Date Title
TWI831916B (zh) 包含tno155和瑞博西尼之藥物組合
AU2002210993B2 (en) Medicinal compositions for concominant use as anticancer agents
JP7223998B2 (ja) Ａｘｌ阻害剤を有効成分として含む固形がん治療剤
JP5898074B2 (ja) キナーゼ阻害作用を有する化合物の併用による抗腫瘍剤
RU2580609C2 (ru) Противоопухолевое терапевтическое средство
TWI726362B (zh) Bcl-2抑制劑與利妥昔單抗和/或苯達莫司汀或Bcl-2抑制劑與CHOP聯合用藥的協同抗腫瘤作用
US9023861B2 (en) Anticancer combination of artemisinin-based drugs and other chemotherapeutic agents
CN113490493A (zh) 治疗脂肪性肝病和/或脂肪性肝炎的方法
CN104436194B (zh) 具有协同增效作用的抗癌组合物
US20250134872A1 (en) Antitumor composition
AU2022250707B2 (en) A pi3k-delta inhibitor for the treatment of pancreatic cancer
TW202114694A (zh) 四環化合物及其鹽類、組合物、及彼等之使用方法
TW202337469A (zh) 治療小細胞肺癌之方法
CN101357134A (zh) 抗肿瘤效果增强剂和抗肿瘤剂
CN118076583A (zh) 用于治疗癌症的方法和组合物
US20240366610A1 (en) Methods and compositions for treating cancer
JP2026510002A (ja) Ｅｔｂｒ活性化に関連する癌を処置するための方法
PT1757283E (pt) Potenciador do efeito antitumoral, agente antitumoral e método para a terapia do cancro
US20240252490A1 (en) Combination Therapies Comprising Kras Inhibitors and SPH2 Inhibitors
JP6553726B2 (ja) 腫瘍治療剤
JP6691971B2 (ja) 慢性骨髄性白血病を治療又は寛解するための医薬組成物
CN118159538A (zh) 含met受体酪氨酸激酶抑制剂的药物组合及应用
WO2025226724A1 (en) Bcr-abl1 inhibitors for use in treating cancer
EA051985B1 (ru) Противоопухолевая композиция
HK40054971A (en) Method for treating fatty liver disease and/or steatohepatitis

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination